Nature Medicine
11, 861 - 866 (2005)
Published online: 10 July 2005; | doi:10.1038/nm1278
Thiazolidinediones expand body fluid volume through PPAR stimulation of ENaC-mediated renal salt absorptionYouFei Guan1, 2, Chuanming Hao1, 2, Dae Ryong Cha1, 2, Reena Rao1, 2, Wendell Lu1, 2, Donald E Kohan1, 3, 4, Mark A Magnuson2, 5, Reyadh Redha1, 2, Yahua Zhang1, 2
& Matthew D Breyer1, 2, 4, 51
Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, 21st Avenue South at Garland Avenue, Nashville, Tennessee
37232, USA. 2
S3223 MCN Vanderbilt University School of Medicine, 21st Avenue South at Garland Avenue, Nashville, Tennessee
37232, USA. 3
Department of Nephrology, School of Medicine, University of Utah Medical Center, 50 North Medical Drive, Salt Lake City, Utah
84132-2412, USA. 4
Veterans Affairs Medical Center, 1310 24th Avenue South, Nashville, Tennessee
37212, USA. 5
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 21st Avenue South at Garland Avenue, Nashville, Tennessee
37232, USA.
Correspondence should be addressed to Matthew D Breyer matthew.breyer@vanderbilt.edu Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator-activated receptor- (PPAR , encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct−specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Pparg
flox/flox mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaC ) expression through a PPAR -dependent pathway. These studies identify Scnn1g as a PPAR target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|